Vancomycin removal and pharmacokinetics during accelerated venovenous hemofiltration. 2024

Natasha D Lopez, and Michael Griggs, and Jonathan H Sin, and Russel J Roberts, and Andrew S Allegretti
Department of Pharmacy, Massachusetts General Hospital, Boston, Massachusetts, USA.

BACKGROUND Vancomycin pharmacokinetics are affected by renal replacement therapy and physiologic changes in critically ill patients. Literature regarding vancomycin removal and pharmacokinetics during accelerated venovenous hemofiltration (AVVH), a form of prolonged intermittent renal replacement therapy, is limited. OBJECTIVE To describe the removal and pharmacokinetics of vancomycin during AVVH. METHODS Eighteen critically ill adults receiving vancomycin and AVVH were included. Vancomycin serum concentrations were obtained within 4 h before and 2-6 h after the AVVH session. Patients' serum concentrations were plotted against time, and individual pharmacokinetic parameters were determined by a one-compartmental analysis. Continuous data are reported as a median (interquartile range [IQR]) and categorical data as a percentage. RESULTS The median AVVH effluent rate was 39.3 mL/kg/h (IQR 35.5-48 mL/kg/h) for a duration of 9 h (IQR 8-9.75 h). AVVH decreased vancomycin concentrations by 29.8% (IQR 24.9%-35.9%), at a rate of 3.4% per hour (IQR 3.1%-4.3% per hour) of AVVH. The vancomycin elimination rate constant and half-life were 0.039 h-1 (IQR 0.036-0.053 h-1 ) and 17.6 h (IQR 13.1-18.8 h), respectively. The area under the curve during AVVH was 171.7 mg*h/L (IQR 149.1-190 mg*h/L). The volume of distribution in 10 patients was 1 L/kg (IQR 0.73-1.1 L/kg). After AVVH, vancomycin 1000 mg (IQR 750-1000 mg) was needed to maintain a serum trough concentration ≥15 mg/L. CONCLUSIONS Vancomycin is significantly removed by AVVH, which requires supplemental dosing after completion of the AVVH session to maintain desired serum concentrations. Therapeutic drug monitoring of vancomycin serum concentrations is recommended for patients undergoing AVVH.

UI MeSH Term Description Entries
D006440 Hemofiltration Extracorporeal ULTRAFILTRATION technique without HEMODIALYSIS for treatment of fluid overload and electrolyte disturbances affecting renal, cardiac, or pulmonary function. Arteriovenous Hemofiltration,Venovenous Hemofiltration,Arteriovenous Hemofiltrations,Hemofiltration, Arteriovenous,Hemofiltration, Venovenous,Hemofiltrations,Venovenous Hemofiltrations
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000079664 Continuous Renal Replacement Therapy Procedures with continuous blood purification (e.g., dialysis, filtration or perfusion) via vascular access designed to mimic kidney function in kidney diseases (e.g., ACUTE RENAL FAILURE and poisoning). CAVHD,CRRT Technique,CVVH Technique,CVVHD,CVVHDF,Continuous Arterio-Venous Ultrafiltration,Continuous RRT,Continuous Renal Replacement Procedure,Continuous Veno-Venous Hemodiafiltration,Continuous Veno-Venous Hemodialysis,Continuous Veno-Venous Hemofiltration,Continuous Venovenous Hemodiafiltration,Continuous Venovenous Hemodialysis,Continuous Venovenous Hemofiltration,Hemofiltration, Continuous Arteriovenous,SCUF Technique,Slow Continuous Ultrafiltration,Arterio-Venous Ultrafiltration, Continuous,Arteriovenous Hemofiltration, Continuous,CVVH Techniques,Continuous Arterio Venous Ultrafiltration,Continuous Arterio-Venous Ultrafiltrations,Continuous Arteriovenous Hemofiltration,Continuous Arteriovenous Hemofiltrations,Continuous RRTs,Continuous Veno Venous Hemodiafiltration,Continuous Veno Venous Hemodialysis,Continuous Veno Venous Hemofiltration,Continuous Veno-Venous Hemodiafiltrations,Continuous Veno-Venous Hemodialyses,Continuous Veno-Venous Hemofiltrations,Continuous Venovenous Hemodiafiltrations,Continuous Venovenous Hemodialyses,Continuous Venovenous Hemofiltrations,Hemodiafiltration, Continuous Veno-Venous,Hemodiafiltration, Continuous Venovenous,Hemodialysis, Continuous Veno-Venous,Hemodialysis, Continuous Venovenous,Hemofiltration, Continuous Veno-Venous,Hemofiltration, Continuous Venovenous,RRT, Continuous,SCUF Techniques,Slow Continuous Ultrafiltrations,Ultrafiltration, Continuous Arterio-Venous,Veno-Venous Hemodiafiltration, Continuous,Veno-Venous Hemodialyses, Continuous,Veno-Venous Hemodialysis, Continuous,Veno-Venous Hemofiltration, Continuous,Venovenous Hemodiafiltration, Continuous,Venovenous Hemodialysis, Continuous,Venovenous Hemofiltration, Continuous
D000079763 Intermittent Renal Replacement Therapy Procedures with non-continuous blood purification (e.g., dialysis, filtration and/or perfusion) via vascular access by increasing blood flow rate compared to CONTINUOUS RRT. Accelerated Veno-Venous Hemofiltration,Accelerated Venovenous Hemofiltration,IRRT Technique,Intermittent RRT,Intermittent Veno-Venous Hemodiafiltration,Intermittent Venovenous Hemodiafiltration,PIRRT,Prolonged Intermittent Renal Replacement Therapy,Accelerated Veno Venous Hemofiltration,Hemodiafiltration, Intermittent Veno-Venous,Hemodiafiltration, Intermittent Venovenous,Hemofiltration, Accelerated Veno-Venous,Hemofiltration, Accelerated Venovenous,IRRT Techniques,Intermittent RRTs,Intermittent Veno Venous Hemodiafiltration,Intermittent Veno-Venous Hemodiafiltrations,Intermittent Venovenous Hemodiafiltrations,RRT, Intermittent,Technique, IRRT,Veno-Venous Hemofiltration, Accelerated,Venovenous Hemodiafiltration, Intermittent,Venovenous Hemofiltration, Accelerated
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D014640 Vancomycin Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear. AB-Vancomycin,Diatracin,VANCO-cell,Vanco Azupharma,Vanco-saar,Vancocin,Vancocin HCl,Vancocine,Vancomicina Abbott,Vancomicina Chiesi,Vancomicina Combino Phar,Vancomicina Norman,Vancomycin Hexal,Vancomycin Hydrochloride,Vancomycin Lilly,Vancomycin Phosphate (1:2),Vancomycin Phosphate (1:2), Decahydrate,Vancomycin Sulfate,Vancomycin-ratiopharm,Vancomycine Dakota,Hydrochloride, Vancomycin,Sulfate, Vancomycin
D016638 Critical Illness A disease or state in which death is possible or imminent. Critically Ill,Critical Illnesses,Illness, Critical,Illnesses, Critical

Related Publications

Natasha D Lopez, and Michael Griggs, and Jonathan H Sin, and Russel J Roberts, and Andrew S Allegretti
February 1991, DICP : the annals of pharmacotherapy,
Natasha D Lopez, and Michael Griggs, and Jonathan H Sin, and Russel J Roberts, and Andrew S Allegretti
January 2014, Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia,
Natasha D Lopez, and Michael Griggs, and Jonathan H Sin, and Russel J Roberts, and Andrew S Allegretti
June 2011, Therapeutic drug monitoring,
Natasha D Lopez, and Michael Griggs, and Jonathan H Sin, and Russel J Roberts, and Andrew S Allegretti
October 1999, Intensive care medicine,
Natasha D Lopez, and Michael Griggs, and Jonathan H Sin, and Russel J Roberts, and Andrew S Allegretti
September 1998, Antimicrobial agents and chemotherapy,
Natasha D Lopez, and Michael Griggs, and Jonathan H Sin, and Russel J Roberts, and Andrew S Allegretti
January 2015, Antimicrobial agents and chemotherapy,
Natasha D Lopez, and Michael Griggs, and Jonathan H Sin, and Russel J Roberts, and Andrew S Allegretti
March 2013, The Annals of pharmacotherapy,
Natasha D Lopez, and Michael Griggs, and Jonathan H Sin, and Russel J Roberts, and Andrew S Allegretti
August 2016, Neurocritical care,
Natasha D Lopez, and Michael Griggs, and Jonathan H Sin, and Russel J Roberts, and Andrew S Allegretti
May 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation,
Natasha D Lopez, and Michael Griggs, and Jonathan H Sin, and Russel J Roberts, and Andrew S Allegretti
June 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation,
Copied contents to your clipboard!